The Latest News from All Areas of Fitness & Wellness

Eli Lilly Halts Bimagrumab Obesity Trial Just Weeks After Launch

Eli Lilly & Co. (NYSE: LLY) has made the decision to end a mid-stage trial of its experimental drug, bimagrumab, intended for obesity patients with type 2 diabetes, just weeks…